Taygan Yilmaz1, Miguel Cordero-Coma. 1. Harvard Vanguard Medical Associates, Department of Visual Services, 133 Brookline Avenue, Boston, MA 02215, USA. Taygan.yilmaz@gmail.com
Abstract
INTRODUCTION: This systematic review assesses the effectiveness of intravitreal bevacizumab (IVB) versus a comparison group in the treatment of branch retinal vein occlusion (BRVO)-associated macular edema, and explores its effects on visual acuity (VA) and central macular thickness (CMT). METHODS: The authors searched the following databases: Medline (1950-October week 3, 2011), The Cochrane Library (Issue 10, 2011), EMBASE (up to 24 October 2011), and the TRIP Database (up to 24 October 2011), using no language or other limits. Trials that were included consisted of patients with BRVO-associated macular edema, those comparing a 1.25 mg IVB injection with a comparison group, those reporting both VA and CMT outcomes, and those having a minimum follow-up of 4 weeks. RESULTS: In the four trials comparing IVB with a comparison group, IVB was effective in improving VA and CMT values in the long-term (12 weeks) in patients with BRVO-associated macular edema. Furthermore, statistically significant improvements in VA in the short-term (4 weeks) could also be seen. DISCUSSION: Clinicians should use this review as an indicator that IVB is effective in improving VA and CMT values in the long-term in patients with BRVO-associated macular edema. It is important to note, however, that statistically significant improvements in VA in the short term could be seen. This review's main aim was to serve as an evidence base for potentially using other modalities, such as IVB, which seems to be reserved for certain cases.
INTRODUCTION: This systematic review assesses the effectiveness of intravitreal bevacizumab (IVB) versus a comparison group in the treatment of branch retinal vein occlusion (BRVO)-associated macular edema, and explores its effects on visual acuity (VA) and central macular thickness (CMT). METHODS: The authors searched the following databases: Medline (1950-October week 3, 2011), The Cochrane Library (Issue 10, 2011), EMBASE (up to 24 October 2011), and the TRIP Database (up to 24 October 2011), using no language or other limits. Trials that were included consisted of patients with BRVO-associated macular edema, those comparing a 1.25 mg IVB injection with a comparison group, those reporting both VA and CMT outcomes, and those having a minimum follow-up of 4 weeks. RESULTS: In the four trials comparing IVB with a comparison group, IVB was effective in improving VA and CMT values in the long-term (12 weeks) in patients with BRVO-associated macular edema. Furthermore, statistically significant improvements in VA in the short-term (4 weeks) could also be seen. DISCUSSION: Clinicians should use this review as an indicator that IVB is effective in improving VA and CMT values in the long-term in patients with BRVO-associated macular edema. It is important to note, however, that statistically significant improvements in VA in the short term could be seen. This review's main aim was to serve as an evidence base for potentially using other modalities, such as IVB, which seems to be reserved for certain cases.
Authors: Ingrid U Scott; Allison R Edwards; Roy W Beck; Neil M Bressler; Clement K Chan; Michael J Elman; Scott M Friedman; Craig Michael Greven; Raj K Maturi; Dante J Pieramici; Michel Shami; Lawrence J Singerman; Cynthia R Stockdale Journal: Ophthalmology Date: 2007-08-15 Impact factor: 12.079
Authors: H Noma; H Funatsu; M Yamasaki; H Tsukamoto; T Mimura; T Sone; T Hirayama; H Tamura; H Yamashita; A Minamoto; H K Mishima Journal: Eye (Lond) Date: 2006-07-07 Impact factor: 3.775
Authors: David M Brown; Peter A Campochiaro; Robert B Bhisitkul; Allen C Ho; Sarah Gray; Namrata Saroj; Anthony P Adamis; Roman G Rubio; Wendy Yee Murahashi Journal: Ophthalmology Date: 2011-08 Impact factor: 12.079
Authors: Vincenzo Russo; Antonio Barone; Emanuele Conte; Francesco Prascina; Andrea Stella; Nicola Delle Noci Journal: Retina Date: 2009-04 Impact factor: 4.256
Authors: T C Kreutzer; C S Alge; A H Wolf; D Kook; J Burger; R Strauss; C Kunze; C Haritoglou; A Kampik; S Priglinger Journal: Br J Ophthalmol Date: 2008-01-22 Impact factor: 4.638
Authors: K Kriechbaum; S Michels; F Prager; M Georgopoulos; M Funk; W Geitzenauer; U Schmidt-Erfurth Journal: Br J Ophthalmol Date: 2008-01-22 Impact factor: 4.638